In May 2019, according to an article published by India Brand Equity Foundation, pharmaceutical industry in India was valued at US$ 33000 Million in 2017 and generic drugs (such as magnesium glutamate) account for 20% of the total drugs exports, making India the largest generic drugs supplier in India. Increasing exports of generic drugs from India is expected to propel the growth of magnesium gluconate in the country.
In June 2017, according to National Institute of Health (NIH), Magnesium acts as essential mineral for over 300 enzyme related actions in the body and it is suitable to include magnesium gluconate as a dietary supplements as well as medicines such as laxatives and antacids. Increasing use of magnesium gluconate in the medical sector is expected to drive the growth of magnesium gluconate during the forecast period.
In March 2016, according to the research paper published on National Center for Biotechnology Information, U.S National Library of Medicine, magnesium and potassium glucomate helps to regulate the cardiovascular functions of the body and it is mainly used in a drug named “Rhythmocor”. Growing demand of magnesium glucomate from the cardiovascular drug industry is set to propel the magnesium glucomate globally.